Roche’s remediation and decommissioning programme at its former manufacturing site in Clarecastle, Co Clare has exceeded €207 million, reflecting the continued scale of investment required following the company’s exit from manufacturing operations in Ireland.

Irish Independent coverage of newly filed accounts showed Roche Ireland recorded a pre-tax loss of €59.07 million in 2025, largely driven by environmental and demolition expenditure linked to restoration work at the site.

According to the accounts, environmental and site-related costs totalled €57.6 million during the year, including expenditure associated with remediation activities, demolition works and external project costs. The company also recorded net finance costs during the period.

The latest annual spend represents the largest environmental outlay recorded during the programme to date and brings cumulative remediation expenditure to €207.56 million over six years.

Site decommissioning began in 2020 following Roche’s earlier decision to cease manufacturing activity at Clarecastle, a move that resulted in the loss of 240 jobs and marked the end of one of the region’s longstanding pharmaceutical operations.

Roche stated that remediation activity is focused on returning the 88-acre location to brownfield status to support future redevelopment opportunities.

As part of the next phase, preparations have begun to bring the site to market to identify potential investors capable of developing future industrial activity at the location.

The company stated that remediation remains scheduled for completion in the fourth quarter of 2027 and that project delivery continues in line with established timelines.

The project illustrates the long-term operational and financial commitments increasingly associated with pharmaceutical site closures, where environmental restoration and future land readiness have become significant considerations alongside manufacturing investment decisions.